Exelixis (EXEL) Change in Accured Expenses (2010 - 2026)
Exelixis (EXEL) recorded quarterly Change in Accured Expenses of $4.0 million in Q2 2026, up 1039.15% quarter-over-quarter from $355000.0 in Q1 2026, and down 12.18% on a YoY basis from $4.6 million in Q2 2025.
Exelixis (EXEL) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Exelixis' Change in Accured Expenses history runs 16 years deep, the most recent figure standing at $4.0 million for Q2 2026.
- In Q2 2026, Change in Accured Expenses fell 12.18% year-over-year to $4.0 million; the TTM figure through Apr 2026 stood at $1.3 million (down 83.85% YoY), while the FY2026 annual figure was $1.9 million, up 1374.5% from the prior year.
- Change in Accured Expenses was $4.0 million for Q2 2026 at Exelixis, up from $355000.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $5.1 million in Q2 2023 to a low of -$54.3 million in Q2 2022.
- Historically, Change in Accured Expenses has averaged -$3.4 million across 5 years, with a median of $604500.0 in 2025.
- The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses plunged 5499.1% in 2022, then surged 223.48% in 2025.
- A 5-year view of Change in Accured Expenses shows it stood at -$54.3 million in 2022, then soared by 100.49% to $264000.0 in 2023, then jumped by 410.23% to $1.3 million in 2024, then slumped by 32.96% to $903000.0 in 2025, then soared by 347.84% to $4.0 million in 2026.
- The last three Change in Accured Expenses figures came in at $4.0 million (Q2 2026), $355000.0 (Q1 2026), and $903000.0 (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Accured Exp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 931,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Exelixis | 13.37 Bn | 12.59 Bn | 590.86 Mn | 4.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 4.04 Mn |
| Apr 3, 2026 | 4.04 Mn |
| Jan 2, 2026 | 355,000.00 |
| Jan 2, 2026 | 355,000.00 |
| Oct 3, 2025 | 903,000.00 |
| Oct 3, 2025 | 903,000.00 |
| Jul 4, 2025 | -3.96 Mn |
| Jul 4, 2025 | -3.96 Mn |
| Apr 4, 2025 | 4.61 Mn |
| Apr 4, 2025 | 4.61 Mn |
| Jan 3, 2025 | 854,000.00 |
| Jan 3, 2025 | 854,000.00 |
| Sep 27, 2024 | 1.35 Mn |
| Sep 27, 2024 | 1.35 Mn |
| Jun 28, 2024 | 1.48 Mn |
| Jun 28, 2024 | 1.48 Mn |
| Mar 29, 2024 | -3.83 Mn |
| Mar 29, 2024 | -3.83 Mn |
| Dec 29, 2023 | 264,000.00 |
| Dec 29, 2023 | 264,000.00 |